Sep 12, 2022 / 12:45PM GMT
Sean M. Laaman - Morgan Stanley, Research Division - Australian Healthcare Analyst
Good morning, everybody. I'm Sean Laaman, the Australian Healthcare Analyst here at Morgan Stanley. A pleasure to welcome Bobby Ghoshal and Rob Douglas from ResMed. So welcome, gentlemen. And maybe to kick things off, Rob, if we can have you make some opening remarks.
Robert A. Douglas - ResMed Inc. - President, COO and Interim President of Sleep & Respiratory Care
Sure. Thanks, Sean. Just a bit of a description for ResMed for you all. We're the world's leading digital tech-enabled medical technology company. We're leaders in all of our markets, and our -- we're best known for treating sleep apnea, which is an incredibly common condition.
Our data suggests there's nearly a billion people with sleep apnea. There's only a few tens of millions being treated. So in our core business, we've got huge opportunity.
We have data showing that treating these patients actually makes a huge difference in their life. It actually prolongs their life. We have really good
Resmed Inc at Morgan Stanley Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers